Why sirolimus is used in stents?
The first DES was approved by FDA in April 2003. This stent releases sirolimus, an agent that inhibits vascular smooth-muscle-cell proliferation. To date, four major clinical trials have demonstrated the sirolimus-eluting stent to be safe and effective in preventing restenosis in de novo coronary artery lesions.
Why is everolimus used in stents?
The drug (everolimus) is released over time from the SYNERGY Stent surface into the coronary artery wall to help prevent re-narrowing, which sometimes occurs after the stent is implanted.
What is the treatment for stent restenosis?
The currently available options for treatment of ISR include angioplasty alone, repeat stenting with DES or drug-coated balloons. Several recent studies have compared the available options for treating ISR in an attempt to identify the preferred therapeutic strategy.
What is sirolimus eluting coronary stent?
The SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System is used in patients experiencing symptoms of heart disease due to coronary artery atherosclerotic lesions that are 24 mm or smaller in length and have a diameter that is between 2.25 mm and 4.00 mm in size.
What is rapamycin eluting stents?
Rapamycin, an immunosuppressant drug that demonstrates antiproliferative properties and inhibits smooth muscle cell migration, may deter the intimal hyperplasia that occurs during spontaneous closure and after-stent implantation of the arterial duct.
What does the drug on a stent do?
A drug-eluting stent is coated with a slow-release medication to help prevent blood clots from forming in a stent. Blood clotting in a stent can cause a future blockage (restenosis) and may lead to a heart attack.
Is Synergy stent drug-eluting?
The SYNERGY BP Stent was the first FDA-approved drug-eluting stent with abluminal bioabsorbable polymer coating available in the U.S. It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.
What kind of stent is Synergy stent?
metal stent
The SYNERGY Stent is a metal stent with a special drug coating added to help reduce the chance of the artery becoming blocked again. The drug is released from the stent over the period of time during which re-blockage is most likely to occur.
What is biomime stent?
BioMime. BioMime TM is a Sirolimus Eluting Coronary Stent System with an ultra-thin (65 µm) strut thickness. This next generation (SES) has a Novel Hybrid Design with closed cells (on both ends of the stent) & open cells (in the middle)- this allows for Morphology Mediated Expansion for adequate conformability and lesser edge dissections.
What is sirolimus eluting stent?
The sirolimus-eluting stent (CYPHER ( trade mark )) is a metal stent coated with 140 micro g/cm (2) of sirolimus blended with synthetic polymers. After stent implantation, sirolimus is slowly released causing localized cytostatic inhibition of proliferation of vascular smooth muscle cells in the peri-stent arterial wall over a period
What is the role of sirolimus in the pathophysiology of peri-stent stroke?
After stent implantation, sirolimus is slowly released causing localized cytostatic inhibition of proliferation of vascular smooth muscle cells in the peri-stent arterial wall over a period of about 1 month. Only minimal amounts of sirolimus enter the bloodstream and these appear to be insufficient to be of clinical relevance.
Where is the Cypher stent available?
Since the preliminary results from the First-in-Man feasibility study were presented, the CYPHER stent is currently available in more than 80 countries and has been used by doctors to treat more than 2 million patients worldwide (Cordis Corporation, Warren, New Jersey, USA, press release 26 April 2006).